Supplementary Table 1 Comparison of glomerular IgG4 staining in patients with high and low titers of anti-PLA2R antibodies

Sample	Age	Sex	Cr mg/dl	Alb g/L	Urine protein	Months before biopsy	Diagnosis	Glomerular IgG4 staining (Luminosity units)	Anti-PLA2R
IMN4	38	M	0.9	29	4.93	1	Idiopathic MN	52.37±11.11	High titer
IMN53	69	M	0.98	21.9	6.93	3	Idiopathic MN	47.58±10.87	High titer
IMN55	53	M	0.65	20.6	5.57	6	Idiopathic MN	64.02±11.78	High titer
IMN58	34	M	0.75	22	8.75	4	Idiopathic MN	56.22±9.55	High titer
IMN60	60	M	0.8	23.7	7.56	26	Idiopathic MN	43.82±12.17	High titer
IMN17	27	M	0.73	15.2	13.4	4	Idiopathic MN	50.20±9.53	Low titer
IMN20	31	F	0.67	23.2	3.51	3	Idiopathic MN	56.33±11.60	Low titer
IMN29	64	F	0.7	28.1	4.16	36	Idiopathic MN	46.92±10.10	Low titer
IMN54	29	F	0.68	30.9	4.37	2	Idiopathic MN	61.57±8.61	Low titer
IMN59	44	M	0.92	22.8	3.78	6	Idiopathic MN	39.55±7.42	Low titer

IMN, idiopathic membranous nephropathy. Numbers refer to the patient number with idiopathic MN. Cr, Serum creatinine. Alb, Serum albumin. Urine protein is presented as urine protein-to-creatinine ratio collected during 24 hours at the time point when biopsy was performed and serum sample was collected. Months

before biopsy reflect the time in months between the initial proteinuria and renal biopsy.

Glomerular IgG4 staining: The sections were examined by epifluorescent microscopy that used a Nikon Pan Fluor lens. The images were captured with a Spot CCD camera and exported into Adobe Photoshop. All exposure settings were kept constant for each group of kidneys. Fluorescence intensity was measured by outlining the perimeter of six glomeruli in each section and reading the luminosity from the Histogram command in Adobe Photoshop. Calibration of the CCD exposure time assured that the settings chosen were in the linear range and well below saturation. There was no difference of IgG4 immunostaining in glomeruli of patients with high titers and low titers of anti-PLA2R antibodies ($P>0.05$).

Supplementary Table 2 Clinical information for patients with idiopathic MN

Sample	Age	Sex	Cr mg/dl	Alb g/L	Urine protein	Time before biopsy	Diagnosis	stages	Treatment after biopsy	Remission (mo)	Relapse	Anti-PLA2R
IMN1	64	M	2.5	24.8	4.18	5	Idiopathic MN	NA	CSA,TW	CR(48)	Yes	POS
IMN3	40	F	0.45	25.1	5.22	18	Idiopathic MN	NA	CSA	CR(26)	No	POS
IMN4	38	M	0.9	29	4.93	1	Idiopathic MN	NA	FK	CR(7)	Yes	POS
IMN5	56	F	0.41	26.9	9.92	12	Idiopathic MN	NA	CSA	CR(4)	No	POS
IMN6	53	M	0.8	24.1	4.48	3	Idiopathic MN	NA	CSA	CR(10)	No	POS
IMN7	47	M	0.72	24.6	5.08	2	Idiopathic MN	NA	CTX	CR(4)	No	POS
IMN9	25	M	0.91	23.5	6.38	6	Idiopathic MN	NA	CTX,TW	CR(9)	No	POS
IMN10	40	M	0.75	19.8	7.43	1	Idiopathic MN	Ⅱ	CSA	NR		POS
IMN11	37	F	0.76	31.3	7.4	1	Idiopathic MN	NA	TW	CR(10)	No	POS
IMN13	57	M	0.84	26.4	4.1	12	Idiopathic MN	NA	CTX	CR(12)	Yes	POS
IMN16	50	M	0.85	14.2	4.48	2	Idiopathic MN	Ⅰ-Ⅱ	TW	CR(4)	No	POS
IMN19	40	M	0.61	17.2	9.24	1	Idiopathic MN	NA	TW	CR(14)	NA	POS
IMN21	24	M	1.06	20.8	6.77	17	Idiopathic MN	Ⅱ	CTX,TW	PR(20)	No	POS

IMN22	59	M	0.59	20.8	4.73	2	Idiopathic MN	NA	CTX	NR		POS
IMN23	61	F	0.78	21.8	6.89	9	Idiopathic MN	NA	TW	CR(14)	No	POS
IMN24	72	M	1.4	21.9	8.24	3	Idiopathic MN	NA	TW	NR		POS
IMN25	59	M	1.5	31.2	3.51	10	Idiopathic MN	NA	TW	CR(24)	No	POS
IMN26	18	F	0.4	17.4	6.5	4	Idiopathic MN	Ⅱ	CSA,TW	PR(24)	Yes	POS
IMN27	49	M	3.92	37.2	6.5	12	Idiopathic MN	Ⅲ	TW	CR(20)	No	POS
IMN28	47	M	0.92	20.8	11.27	1	Idiopathic MN	Ⅱ	TW	NR		POS
IMN30	59	M	0.84	27.9	9.89	2	Idiopathic MN	NA	TW	NA		POS
IMN31	77	M	0.89	24.9	8.49	NA	Idiopathic MN	NA	TW	NR		POS
IMN32	71	M	0.66	31.3	5.11	1	Idiopathic MN	NA	TW	CR(20)	No	POS
IMN33	66	M	0.65	21.2	6.01	1	Idiopathic MN	NA	TW	NR		POS
IMN34	22	M	0.6	23.8	10.96	5	Idiopathic MN	NA	TW	CR(24)	No	POS
IMN35	54	M	0.57	29.6	4.23	5	Idiopathic MN	NA	TW	NA		POS
IMN36	42	M	0.79	26.7	3.72	6	Idiopathic MN	Ⅰ-Ⅱ	TW	NR		POS
IMN37	64	F	0.98	20	7.63	2	Idiopathic MN	Ⅱ	CTX,CSA	CR(24)	Yes	POS
IMN38	62	M	0.8	26.9	9.52	3	Idiopathic MN	Ⅱ	CTX,MMF,TW	NR		POS

IMN39	39	M	0.75	26.5	4.38	36	Idiopathic MN	NA	TW	NR		POS
IMN40	46	M	0.81	33	6.75	3	Idiopathic MN	II	TW	NR		POS
IMN41	34	M	0.75	21.8	6.87	2	Idiopathic MN	III-4	CTX,TW	NR		POS
IMN42	42	M	0.98	26.4	4.41	1	Idiopathic MN	II	CSA	NA		POS
IMN43	68	M	0.94	29.7	3.63	84	Idiopathic MN	NA	TW	NA		POS
IMN44	27	M	0.64	22.4	4.84	2	Idiopathic MN	I - II	TW	CR(36)	NA	POS
IMN45	58	M	0.64	22.5	6.37	18	Idiopathic MN	NA	TW	CR(12)	NA	POS
IMN46	39	M	0.83	30	7.47	3	Idiopathic MN	III-IV	TW	CR(12)	NO	POS
IMN47	39	M	0.90	23.9	3.98	1	Idiopathic MN	NA	TW	NR		POS
IMN48	39	F	0.58	33.5	3.99	5	Idiopathic MN	II	TW	CR(16)	NO	POS
IMN49	61	M	0.91	19.4	4.57	16	Idiopathic MN	NA	TW	NR		POS
IMN50	18	M	0.91	28.7	9.42	1	Idiopathic MN	NA	TW	PR(12)	Yes	POS
IMN51	46	F	0.41	27.4	5.06	10	Idiopathic MN	I	TW	NR		POS
IMN52	64	M	0.98	22.9	4.33	1	Idiopathic MN	III-IV	TW	NA		POS
IMN53	69	M	0.98	21.9	6.93	3	Idiopathic MN	NA	TW	NR		POS
IMN55	53	M	0.65	20.6	5.57	6	Idiopathic MN	NA	TW	NR		POS

IMN56	43	M	0.64	18.9	13.5	1	Idiopathic MN	NA	TW	CR(18)	NA	POS
IMN57	67	F	0.72	23.5	3.61	5	Idiopathic MN	NA	TW	NR		POS
IMN58	34	M	0.75	22	8.75	4	Idiopathic MN	II	TW	NA		POS
IMN60	60	M	0.8	23.7	7.56	26	Idiopathic MN	NA	CTX,TW	NR		POS
IMN18	18	M	0.88	19.7	5.07	2	Idiopathic MN	II	TW	CR(3)	NA	NEG
IMN2	29	M	0.74	37.3	4.8	6	Idiopathic MN	II	MMF	CR(4)	No	Low titer
IMN8	66	F	0.62	28.4	4.44	12	Idiopathic MN	NA	TW,CSA	NR		Low titer
IMN12	37	F	0.46	24.8	5.27	1	Idiopathic MN	NA	TW	CR(3)	No	Low titer
IMN14	42	F	0.73	26.6	9.85	4	Idiopathic MN	II	TW	CR(24)	Yes	Low titer
IMN15	44	F	0.8	17.8	8.2	1	Idiopathic MN	II	TW	NA	NA	Low titer
IMN17	27	M	0.73	15.2	13.4	4	Idiopathic MN	NA	TW	CR(4)	Yes	Low titer
IMN20	31	F	0.67	23.2	3.51	3	Idiopathic MN	III-IV	FK	CR(6)	No	Low titer
IMN29	64	F	0.7	28.1	4.16	36	Idiopathic MN	NA	TW	NR		Low titer
IMN54	29	F	0.68	30.9	4.37	2	Idiopathic MN	II	TW	CR(8)	No	Low titer
IMN59	44	M	0.92	22.8	3.78	6	Idiopathic MN	II	TW	CR(12)	No	Low titer

IMN, idiopathic membranous nephropathy. Numbers refer to the patient number with idiopathic MN. Cr, Serum creatinine. Alb, Serum albumin. Urine protein is presented as urine protein-to-creatinine ratio collected during 24 hours at the time point when biopsy was performed and serum sample was collected.

Months before biopsy reflect the time in months between the initial proteinuria and renal biopsy. Stages were determined by electron microscope observations. NA, not available. Treatment indicates immunosuppressive therapy after the diagnosis of idiopathic MN based on biopsy. TW, Tripterygium wilfordii hook F. CTX, cyclophosphamide. MMF, mycophenylate mofetil. FK, FK506(tacrolimus). CSA, cyclosporine. None, no immunosuppressive therapy. Most proteinuric patients were also being treated with angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers, and diuretics. Remission time reflects the time in months after the diagnosis of idiopathic MN, either complete remission (CR) or partial remission (PR). Complete remission was defined by proteinuria <0.3 g/24hr and normalized serum albumin concentration at least for 1 month. Partial remission was defined as proteinuria less than 3.5 g/24 hr and 50% lower than baseline proteinuria. NR, no remission.

NEG: negative. POS, positive.

Supplementary Table 3 Clinical information for patients with idiopathic MN in remission

Sample	Age	Sex	Cr mg/dl	Alb g/L	Urine protein	Months before biopsy	Stages	Diagnosis	Treatment	Remission time(mo)	Relapse	Anti-PLA2R
MNR1	49	F	0.77	34	0.75	6	NA	Idiopathic MN	None	6	No	NEG
MNR3	52	F	0.54	35.4	0.6	8	Ⅱ	Idiopathic MN	MMF,TW	10	No	NEG
MNR4	34	F	0.46	40.9	0.44	4	Ⅱ-Ⅲ	Idiopathic MN	TW	4	No	NEG
MNR5	28	M	0.74	38.8	0.6	NA	NA	Idiopathic MN	TW	12	NA	NEG
MNR7	49	F	0.62	31.6	0.38	4	Ⅰ	Idiopathic MN	TW	10	No	NEG
MNR8	42	F	0.67	36.5	0.72	4	Ⅱ	Idiopathic MN	TW	12	NA	NEG
MNR10	54	F	0.34	43.6	0.59	6	NA	Idiopathic MN	TW	5	No	NEG
MNR12	41	M	0.75	47.9	0.53	2	NA	Idiopathic MN	NA	4	No	NEG
MNR13	37	F	0.65	33.2	0.86	10	NA	Idiopathic MN	TW	6	No	NEG
MNR17	38	F	0.49	31.1	0.64	5	Ⅰ-Ⅱ	Idiopathic MN	TW	5	No	NEG
MNR2	67	M	0.96	38.1	0.56	2	NA	Idiopathic MN	TW	6	No	Low titer
MNR9	40	M	0.78	32.1	0.63	NA	NA	Idiopathic MN	TW	5	No	Low titer
MNR14	23	F	0.46	30.1	0.84	5	NA	Idiopathic MN	NA	5	No	Low titer

MNR15	45	F	0.71	43.3	0.1	36	NA	Idiopathic MN	TW	6	No	Low titer
MNR19	65	M	0.86	33.2	0.53	2	NA	Idiopathic MN	TW	12	NA	Low titer
MNR21	53	F	1.07	32.6	0.77	24	II	Idiopathic MN	TW	12	No	Low titer
MNR22	32	F	0.55	35.9	0.86	5	NA	Idiopathic MN	NA	6	No	Low titer
MNR6	37	F	0.58	31.4	0.23	1	II	Idiopathic MN	TW	6	No	POS
MNR11	43	M	0.8	34.6	0.77	6	II	Idiopathic MN	FK,TW	6	Yes	POS
MNR16	36	F	0.45	35.3	0.47	NA	II-III	Idiopathic MN	TW	6	Yes	POS
MNR23	47	M	0.78	39.5	0.41	12	NA	Idiopathic MN	TW	10	No	POS

MNR, idiopathic membranous nephropathy in remission. Numbers refer to the patient number. Cr, Serum creatinine. Alb, Serum albumin. Urine protein is presented as urine protein-to-creatinine ratio collected during 24 hours.

Months before biopsy reflect the time in months between the initial proteinuria and the date of first biopsy. Stages were determined by electron microscope observations. NA, not available. Treatment indicates immunosuppressive therapy after the diagnosis of idiopathic MN based on biopsy. TW, Tripterygium wilfordii hook F. MMF, mycophenylate mofetil. FK,FK506 (tacrolimus). None, no immunosuppressive therapy. Most proteinuric patients were also being treated with angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers, and diuretics. Remission time reflect the time in months after the diagnosis of idiopathic MN.

NEG: negative. POS, positive.

Supplementary Table 4 Clinical information for patients with Lupus-MN

Sample	Age	Sex	Cr mg/dl	Alb g/L	Urine protein	ANA	Ads-DNA	ACL	C3 g/L	C4 g/L	Months before biopsy	Treatment	Anti-PLA2R
LMN1	38	F	0.63	17.5	9.44	1:1024	NEG	NEG	0.34	0.13	2	MMF	NEG
LMN2	51	F	0.50	20.9	4.79	1:256	NEG	NEG	0.45	0.25	3	TW	NEG
LMN3	26	F	0.72	28.2	6.60	1:256	NEG	NEG	1.04	0.23	96	NA	NEG
LMN4	22	F	0.65	28	5.76	1:512	NEG	+	0.56	0.22	2	NA	NEG
LMN5	31	F	0.64	15.5	14.43	1:1024	+ (1:10)	+	0.38	0.11	15	TW	NEG
LMN6	42	F	0.61	22.9	3.56	1:64	NEG	NEG	0.92	0.11	84	NA	NEG
LMN7	21	F	0.60	18.7	6.52	1:256	NEG	NEG	0.80	0.10	5	FK	NEG
LMN8	58	F	1.17	17.8	4.22	1:256	NEG	+	0.77	0.09	8	NA	NEG
LMN9	15	M	0.83	19.0	7.56	1:256	NEG	NEG	0.84	0.25	6	FK,TW	NEG
LMN10	16	F	0.46	21.2	4.79	1:256	NEG	+	0.67	0.17	1	FK	NEG
LMN11	37	F	0.57	27.9	5.62	1:512	NEG	NEG	0.78	0.12	12	CTX	NEG
LMN12	22	F	0.72	23.4	3.98	1:16	NEG	NEG	0.43	0.22	48	NA	NEG
LMN13	38	F	1.05	33.8	4.97	1:256	+ (1:10)	NEG	0.98	0.22	12	TW	NEG

LMN14	30	M	0.52	27.7	4.51	1:1024	+ (1:10)	NEG	0.27	0.05	7	TW	NEG
LMN15	21	M	0.69	29.2	4.96	1:1024	+ (1:10)	NEG	0.45	0.08	1	CTX	NEG
LMN16	65	F	1.02	22.6	4.39	1:128	NEG	NEG	0.80	0.20	36	TW	NEG
LMN17	29	F	1.46	15.7	4.73	1:512	NEG	NEG	0.56	0.23	36	TW	NEG
LMN18	13	M	0.98	20.8	5.73	1:512	NEG	NEG	0.61	0.19	NA	NA	POS
LMN19	43	F	0.65	24.2	3.51	1:128	NEG	+	0.75	0.21	8	TW	NEG
LMN20	32	F	0.70	30.3	4.26	1:256	+ (1:10)	NEG	0.47	0.12	60	TW	NEG

LMN, lupus membranous nephropathy. Numbers refer to the patient number. Cr, Serum creatinine. Alb, Serum albumin. Urine protein is presented as urine protein-to-creatinine ratio collected during 24 hours at the time point when biopsy was performed and serum sample was collected. ANA, antinuclear antibody. Ads-DNA, anti-double-stranded DNA. ACL, anticardiolipid antibody.

Months before biopsy reflect the time in months between the initial proteinuria and renal biopsy. Treatment indicates immunosuppressive therapy after the diagnosis of lupus membranous nephropathy. TW, Tripterygium wilfordii hook F. CTX, cyclophosphamide. MMF, mycophenylate mofetil. FK,FK506 (tacrolimus). CSA, cyclosporine. NA, not available. Most proteinuric patients were also being treated with angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers, and diuretics.

NEG: negative. POS, positive.

Supplementary Table 5 Relevant clinical information about patients with hepatitis B-associated MN

Sample	Age	Sex	Cr mg/dl	Alb g/L	Urine protein	Hepatitis B serology tests					ALT (IU/L)	Months before biopsy	Treatment	Remission	Anti-PLA2R
						HBSAg	HBeAb	HBeAg	HBeAb	HBcAb					
HBMN1	37	M	0.62	23.4	4.18	+	-	-	+	+	81	NA	Lamivudine	CR	NEG
HBMN2	43	F	0.79	25.6	8.06	-	-	+	-	+	90	NA	Lamivudine	NA	NEG
HBMN3	42	M	0.22	29.8	5.91	+	-	-	+	+	100	60	Lamivudine, TW	CR	NEG
HBMN4	41	M	0.85	20.6	6.30	+	-	-	+	+	86	3	Lamivudine	CR	NEG
HBMN5	30	M	0.68	21.0	10.39	+	-	-	+	+	28	2	Lamivudine, TW	CR	NEG
HBMN6	23	M	0.79	15.2	6.20	+	-	+	-	+	23	6	Lamivudine	CR	NEG
HBMN7	8	M	0.31	21.7	4.13	+	-	+	-	+	22	1	IFN-alpha	CR	NEG
HBMN8	50	M	0.67	16.3	10.68	+	-	-	+	+	30	3	Lamivudine	NR	Low titer
HBMN9	29	M	0.52	17.6	4.70	+	-	+	-	+	152	8	Lamivudine	CR	NEG
HBMN10	22	M	0.78	18.8	9.62	+	-	-	+	+	22	4	Lamivudine, TW	NR	Low titer
HBMN11	16	M	0.46	30.8	5.51	+	-	+	-	+	67	5	Lamivudine	CR	NEG
HBMN12	27	M	1.45	29.1	10.01	+	-	+	-	+	22	36	Lamivudine	NR	POS

HBMN13	51	F	0.44	24.7	6.06	+	-	+	-	+	57	2	Lamivudine	CR	NEG
HBMN14	14	F	0.45	30.8	3.58	+	-	+	-	+	44	2	Telbivudine	CR	NEG
HBMN15	45	M	0.85	24.9	3.83	+	-	+	-	+	91	2	Entecavir	CR	NEG
HBMN16	37	M	0.80	26.6	4.67	+	-	+	-	+	65	1	Lamivudine	NA	NEG

HBMN, hepatitis B-associated MN. Numbers refer to the patient number. Cr, Serum creatinine. Alb, Serum albumin. Urine protein is presented as urine protein-to-creatinine ratio collected during 24 hours at the time point when biopsy was performed and serum sample was collected. ALT, Alanine aminotransferase.

Months before biopsy reflect the time in months between the initial proteinuria and renal biopsy.

Treatment indicates anti-viral therapy after the diagnosis of hepatitis B-associated MN based on biopsy. TW, Tripterygium wilfordii hook F. NA, not available. CR, complete remission, which was defined by proteinuria <0.3 g/24hr and normalized serum albumin concentration at least for 1 month. NR, no remission.

NEG: negative. POS, positive.

Supplementary Table 6 Relevant clinical information about patients with tumor-associated MN

Sample	Age	Sex	Cr mg/dl	Alb g/L	Urine protein	Time of tumor	Resection	Associated therapies	Remission	Outcome	Type of cancer	Histology of cancer	C3	IgG1	IgG4	Anti-PLA2R
TUMN1	55	M	0.53	25.6	6.31	0	no	none	NR	death	lung	Adenocarcinoma	2+	2+	-	NEG
TUMN3	47	F	0.55	23.7	7.06	0	surgery	Chemotherapy	NR	death	colon	Adenocarcinoma	2+	2+	-	NEG
TUMN5	59	M	0.80	16.4	6.97	0	surgery	TW	CR	alive	tongue	clear-cell carcinoma	2+	2+	-	NEG
TUMN7	40	M	1.13	42.4	1.72	6	surgery	Chemotherapy	CR	alive	lung	Squamous cell carcinoma	1+	2+	-	NEG
TUMN8	54	M	0.58	28.5	3.14	0	surgery	Chemotherapy	NR	death	stomach	Adenocarcinoma	1+	2+	-	NEG
TUMN9	52	M	0.90	26.6	5.18	0	no	Chemotherapy	NR	alive	lung	Squamous cell carcinoma	2+	2+	-	NEG
TUMN10	53	M	0.62	22.3	3.94	0	no	Chemotherapy	NR	alive	lung	Squamous cell carcinoma	2+	2+	-	NEG
TUMN2	65	M	0.64	31.1	2.11	0	surgery	Chemotherapy, TW	NR	alive	stomach	Adenocarcinoma	2+	2+	2+	POS
TUMN4	56	M	0.90	27.9	3.86	0	surgery	Chemotherapy, TW	Relapse	alive	lung	Squamous cell carcinoma	2+	2+	+/-	POS
TUMN6	55	M	1.05	23.6	6.37	0	surgery	Chemotherapy, TW	Relapse	alive	larynx	Squamous cell carcinoma	+	2+	2+	POS

TUMN, tumor-associated MN. Numbers refer to the patient number. Cr, Serum creatinine. Alb, Serum albumin. Urine protein is presented as urine

protein-to-creatinine ratio collected during 24 hours at the time point when biopsy was performed and serum sample was collected.

Time of tumor reflects the time between the diagnosis of tumor and that of MN. In most of the patients, tumor was asymptomatic and recognized by systematic diagnostic procedures triggered by the diagnosis of MN. In one patient (TUMN7), MN was diagnosed 6 months after the diagnosis of lung cancer. Associated therapies, most patients using general chemotherapy protocol after surgery. TW, Tripterygium wilfordii hook F.

Time to remission reflect the time in months after the diagnosis of MN. CR,complete remission, which was defined by proteinuria <0.3 g/24hr and normalized serum albumin concentration at least for 1 month. NR, no remission. In 7 patients without anti-PLA2R autoantibodies, 2 patients went into complete remission of proteinuria after tumor remission, three patients died as a direct or indirect result of tumors; the other 2 patients remained alive but had persistent proteinuria without tumor resection. Relapse, two patients had complete remission of proteinuria after resection of their tumors, but relapse of proteinuria. C3,IgG1,IgG4 reflect the immunofluorescence staining in renal biopsies.

NEG, negative. POS,positive.

Supplementary Table 7 Information about healthy controls

Sample	Age	Sex	Cr mg/dl	Alb g/L	Urine protein
HC1	22	M	0.67	43.9	NEG
HC2	57	M	0.74	40.3	NEG
HC3	59	F	0.79	41.2	NEG
HC4	70	M	0.76	39.2	NEG
HC5	57	F	0.68	39.6	NEG
HC6	18	F	0.69	47.7	NEG
HC7	46	M	0.77	42.3	NEG
HC8	45	M	0.79	46.9	NEG
HC9	60	F	0.96	36.5	NEG
HC10	55	M	0.74	39.2	NEG
HC11	70	M	0.87	39.8	NEG
HC12	59	F	0.64	46.4	NEG
HC13	62	M	0.63	39.7	NEG
HC14	25	F	0.69	47.4	NEG
HC15	55	M	0.77	42.5	NEG
HC16	40	M	0.72	44.8	NEG
HC17	62	F	0.96	43.9	NEG
HC18	61	M	0.71	39.5	NEG
HC19	40	M	0.79	49.4	NEG
HC20	45	F	0.86	45.7	NEG

HC, healthy control. Numbers refer to the control number. Cr, Serum creatinine. Alb, Serum albumin. Urine protein is presented as spot urine determined by

urine dipstick. NEG: negative.